Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Spreading Depolarization Suppression
NCT02501941Phase 1Completed
- Sponsor
- The University of New Mexico
- Start
- Jul 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ketamine in traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) (2 arms), sponsored by The University of New Mexico. Primary endpoint: Change in frequency of Cortical Spreading depression with use of ketamine at 7 days. Started Jul 2015; status: completed.
02
Drugs
ketamine
03
Conditions
traumatic brain injury (TBI)subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT02501941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501941.